Matt Campbell

Matt Campbell: The results of *two* Phase 2 studies of cabozantinib in Adrenal Cancer in The Lancet Oncology

Matt Campbell, Genitorurinary medical oncologist at UT MD Anderson Cancer center, shared a post on X:

“HOT OFF THE PRESS: Happy to share the results of *two* Phase 2 studies of cabozantinib in Adrenal Cancer in The Lancet Oncology from MD Anderson Cancer center.”

Matt Campbell: The results of *two* Phase 2 studies of cabozantinib in Adrenal Cancer in The Lancet Oncology

Source: Matt Campbell/X

Adrenal Cancer Cabozantinib cancer Matt Campbell MD Anderson Cancer Center OncoDaily Oncology The Lancet Oncology